NewAmsterdam Pharma Company N.V. - Ordinary Shares (NQ:NAMS)
32.62
-1.74
(-5.08%)
Streaming Delayed Price
Updated: 12:24 PM EST, Jan 12, 2026
Add to My Watchlist
Price and Volume
Detailed Quote| Volume | 258,175 |
| Open | 34.10 |
| Bid (Size) | 32.57 (200) |
| Ask (Size) | 32.68 (100) |
| Prev. Close | 34.37 |
| Today's Range | 32.53 - 34.87 |
| 52wk Range | 14.06 - 42.00 |
| Shares Outstanding | N/A |
| Dividend Yield | N/A |
Top News
More News
Performance
More News
Read More
Investment Powerhouse Backs Biotech Stock to the Tune of $419 Million ↗
November 20, 2025
Biotech Stock Gets Booted in Latest Fund Update ↗
November 19, 2025
Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stock ↗
November 19, 2025
Why Bain Capital Is Selling Shares of This Biotech Stock Now ↗
November 18, 2025
NewAmsterdam (NAMS) Q2 Revenue Jumps 49% ↗
August 06, 2025
Frequently Asked Questions
Is NewAmsterdam Pharma Company N.V. - Ordinary Shares publicly traded?
Yes, NewAmsterdam Pharma Company N.V. - Ordinary Shares is publicly traded.
What exchange does NewAmsterdam Pharma Company N.V. - Ordinary Shares trade on?
NewAmsterdam Pharma Company N.V. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for NewAmsterdam Pharma Company N.V. - Ordinary Shares?
The ticker symbol for NewAmsterdam Pharma Company N.V. - Ordinary Shares is NAMS on the Nasdaq Stock Market
What is the current price of NewAmsterdam Pharma Company N.V. - Ordinary Shares?
The current price of NewAmsterdam Pharma Company N.V. - Ordinary Shares is 32.62
When was NewAmsterdam Pharma Company N.V. - Ordinary Shares last traded?
The last trade of NewAmsterdam Pharma Company N.V. - Ordinary Shares was at 01/12/26 12:24 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
Facebook
Twitter
YouTube